Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Revista de la Facultad de Medicina Humana
versión impresa ISSN 1814-5469versión On-line ISSN 2308-0531
Resumen
PACHECO, Cristian; CALDERON, Mónica; BARRIONUEVO, Carlos y MORENO, Henry Gomez. Anaplastic large T-cell lymphoma: 10-year experience at the National Institute of Neoplastic diseases, Lima - Peru. Rev. Fac. Med. Hum. [online]. 2022, vol.22, n.3, pp.547-555. Epub 09-Jul-2022. ISSN 1814-5469. http://dx.doi.org/10.25176/rfmh.v22i3.5027.
Introduction:
Anaplastic Large T-Cell Lymphoma is an infrequent pathology, determined by the expression of CD30, with different characteristics in its presentation and being more aggressive according to ALK expression.
Objectives:
The present study seeks to determine the epidemiological, clinicopathological, and prognostic characteristics of patients with Anaplastic Large T-Cell Lymphoma.
Methods:
Descriptive, retrospective study of patients diagnosed with Anaplastic Large T-Cell Lymphoma of the National Institute of Neoplastic Diseases (INEN) between 2006 and 2016.
Results:
The pathology of 86 patients was analyzed and reviewed, 57% were men and 33 % women; of the total population, 21.9% were positive for ALK, 48 of the patients were found in CD I and II, and 36 between stages III and IV. 57 patients had low or low-intermediate risk, while 26 had high-intermediate and high risk. The estimated overall survival was 40.8% at 5 years; in the group of patients with ALK + it was 67.4%, and in the group with ALK-, it was estimated at 30.2%.
Conclusions:
Anaplastic Large T-Cell Lymphoma is an aggressive disease with a heterogeneous distribution to age and slightly more frequent in males, with ALK and the international prognostic index as important prognostic factors.
Palabras clave : Anaplastic Large Cell Lymphoma; Anaplastic Lymphoma Kinase; Survival rate. (fuente: MeSH NLM)..